imiquimod has been researched along with u 0126 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Ariffin, JK; Fairlie, DP; Hohenhaus, DM; Iyer, A; Lim, J; Seow, V; Suen, JY; Sweet, MJ | 1 |
2 other study(ies) available for imiquimod and u 0126
Article | Year |
---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a.
Topics: Aminoquinolines; Butadienes; Cells, Cultured; Complement C5a; Extracellular Signal-Regulated MAP Kinases; Granulocyte-Macrophage Colony-Stimulating Factor; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Imiquimod; Inflammation; Interleukin-10; Interleukin-6; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Macrophage Colony-Stimulating Factor; Macrophages; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Monocytes; Nitriles; Pertussis Toxin; Phosphatidylinositol 3-Kinases; Poly I-C; Proto-Oncogene Proteins c-raf; Receptor, Anaphylatoxin C5a; Receptors, Complement; Salmonella typhimurium; Toll-Like Receptor 4; Tumor Necrosis Factors | 2013 |